BOSTON INTERACTOME LLC

Founded 2025 · Biotech · Private

Small-molecule therapeutics targeting protein-protein interactions of epigenetic complexes to treat opioid use disorder

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Founded
2025
Latest Form D
$500K, Jun 2026
Total capital
$898K
Federal grants
$398K
1 award · 2025
Rank in peer group#369 of 502
Private capital raised
$500K
1 Form D · last Jun 2026
4 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20252026FEDERAL ↑EQUITY ↓Cumulative $898K$398K1st Form D$500K
20252026FEDERAL ↑EQUITY ↓Cumulative $898K$398K1st Form D$500K

Latest events

  • Private capital raisedForm D · SEC · 1st filing$500K
  • Federal grantHealth and Human S · Phase I · Developing high-precision epigenetic therapeutics for opioid use disorder$398K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

14months

from BOSTON INTERACTOME LLC’s first federal award to its first private round.

First federal award · Apr 2025
Health and Human S · $398K
First Form D · Jun 2026
$500K · 1st Form D
Awards before first raise
1 award

An association in public records, not a cause or a prediction.

Standing among 502 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Oliver A. WeisserExecutive Officer, DirectorNamed in SEC Form D filings
  • Soon Gang A. ChoiExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .